ISID | Jotup

Idaho Virtual Academy and Insight School of Idaho Enrollment Open for 2024-2025 School Year

Retrieved on:

Friday, February 23, 2024

Technology, Teens, Parenting, Other Technology, Family, Internet, Other Education, Consumer, Primary, Secondary, Education, Tourism, Counselor, School, Restaurant, ISID, Student, Tutoring

Enrollment for the 2024-2025 school year is now open at Idaho Virtual Academy (IDVA) and Insight School of Idaho (ISID), online tuition-free public schools for K-12 students.

Key Points:

Enrollment for the 2024-2025 school year is now open at Idaho Virtual Academy (IDVA) and Insight School of Idaho (ISID), online tuition-free public schools for K-12 students.
Part of the Idaho public school system, IDVA and ISID are online, tuition-free, accredited schools providing kids the opportunity to learn in a remote environment and are available to Idaho K-12 students statewide.
“Our top priority is creating a welcoming, inclusive learning environment for our students,” said Kelly Edginton, IDVA and ISID Executive Director.
IDVA and ISID are now accepting enrollment applications for the 2024-2025 school year.

Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Retrieved on:

Monday, November 27, 2023

Quality of life, Priority review, Food, Concha bullosa, ISID, BLA, FDA, PDUFA, Biologics license application, Advisory Committee, Patient, Safety, Wound healing, COL7A1, Pharmaceutical industry

CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel), Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of May 25, 2024. The FDA also advised that it does not currently plan to convene an Advisory Committee meeting to discuss the pz-cel application.

Key Points:

Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of May 25, 2024.
The FDA also advised that it does not currently plan to convene an Advisory Committee meeting to discuss the pz-cel application.
Both studies revealed that a one-time application of pz-cel on large and chronic wounds delivered sustained wound healing and pain reduction.
The grant of the Priority Review status is an important prerequisite for Abeona’s eligibility for a Priority Review Voucher.

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

Retrieved on:

Tuesday, September 26, 2023

Biologics license application, Priority review, ISID, RDEB, Quality of life, Concha bullosa, Regenerative medicine, Rare, Orphanet Journal of Rare Diseases, Patient, Tissue Engineering and Regenerative Medicine International Society, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Safety, Wound healing, Pharmaceutical industry, New Drug Application

As part of the submission, Abeona requested a Priority Review, which, if granted, would shorten the FDA’s review period to six months from the filing acceptance of the BLA, instead of 10 months under standard review.

Key Points:

As part of the submission, Abeona requested a Priority Review, which, if granted, would shorten the FDA’s review period to six months from the filing acceptance of the BLA, instead of 10 months under standard review.
“We appreciate the FDA’s level of engagement and constructive guidance in the months leading up to the pre-BLA meeting.
If accepted with Priority Review, Abeona expects potential BLA approval in the second quarter of 2024, at which time, Abeona believes that it would be eligible to receive a Priority Review Voucher.
EB-101 has been granted Rare Pediatric Disease, Regenerative Medicine Advanced Therapy, Breakthrough Therapy and Orphan Drug designations.

Mary Kay Inc Presents New Findings on an Antioxidant Blend That Can Reduce the Visible Effects of Pollution and Aging on Skin

Retrieved on:

Tuesday, September 19, 2023

Mary Kay Inc. , a global leader in skin care innovation, recently revealed breakthrough research on a treatment that diminishes the visible effects of pollution and aging on human skin.

Key Points:

Mary Kay Inc. , a global leader in skin care innovation, recently revealed breakthrough research on a treatment that diminishes the visible effects of pollution and aging on human skin.
Scientists at Mary Kay have been investigating the effects of air pollution on skin through multiple academic collaborations since 2016.
Previous efforts have analyzed the biochemical responses of human skin cells to various forms of pollution, including diesel exhaust and urban air pollution.
Mary Kay holds more than 1,600 patents for products, technologies, and packaging designs in its global portfolio.

Fujitsu, ISID, DIPRO start collaboration to realize DX in the manufacturing industry

Retrieved on:

Wednesday, August 23, 2023

PLM, UGS Corp., Partnership, DIGITAL, Information services, ISID, Siemens Digital Industries Software, Fujitsu

TOKYO, Aug 23, 2023 - (JCN Newswire) - Fujitsu, Information Services International-Dentsu, Ltd. (hereinafter ISID) and DIGITAL PROCESS LTD. (hereinafter DIPRO) today announced a collaboration in the area of engineering chains starting August 23 to deliver product life cycle management (hereinafter PLM) systems for customers in the Japanese manufacturing industry.

Key Points:

TOKYO, Aug 23, 2023 - (JCN Newswire) - Fujitsu, Information Services International-Dentsu, Ltd. (hereinafter ISID) and DIGITAL PROCESS LTD. (hereinafter DIPRO) today announced a collaboration in the area of engineering chains starting August 23 to deliver product life cycle management (hereinafter PLM) systems for customers in the Japanese manufacturing industry.
In April 2022, Fujitsu, ISID, a subsidiary of Dentsu Group Inc., and Dentsu Inc. started a strategic partnership toward the realization of customer-oriented transformation aligned with three value chains -- "engineering chain," "supply chain" and "demand chain" -- to contribute to the continued business growth of client companies and the resolution of environmental and societal issues.
As part of this partnership, Fujitsu and ISID announced the launch of a joint project to provide Siemens Digital Industries Software's (1) product life cycle management (PLM) system "Teamcenter," and will work toward achieving digital transformation (DX) in the manufacturing industry in the engineering chain.
DIPRO, a member of the Fujitsu Group, has now joined this joint project, and the three companies have agreed to further strengthen their organization for providing PLM systems.

Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on:

Monday, August 14, 2023

CUPERTINO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing new therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometablolic diseases, today reported financial results for the second quarter ended June 30, 2023 and summarized recent business highlights.

Key Points:

CUPERTINO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing new therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometablolic diseases, today reported financial results for the second quarter ended June 30, 2023 and summarized recent business highlights.
“Brilaroxazine continues to demonstrate a well-tolerated safety profile with a unique potential to improve multiple symptom domains and neuroinflammation in schizophrenia.
As of June 30, 2023, the Company’s cash totaled approximately $11.2 million compared to approximately $18.5 million as of December 31, 2022.
Reviva believes that based on the current operating plan and financial resources, the Company’s cash as of June 30, 2023 will be sufficient to fund current operating plans well into the fourth quarter of 2023.

EveLab Insight Advances Understanding of Skin Aging With AI-Driven Research

Retrieved on:

Monday, June 5, 2023

Wellcome Trust Principal Research Fellow, The Digital Standard, Face, ISID, Ageing, Genoa Joint Laboratories, Woman, Anger, Research, Sadness, Dermatology, Eve M. Troutt Powell, International Society for Infectious Diseases, Human, International Society, Skin, Tongue and groove, Medical device, Cosmetics

Visible signs of aging, such as wrinkles, have been central to the scientific study of skin aging and are a key component of the multibillion-dollar skincare industry.

Key Points:

Visible signs of aging, such as wrinkles, have been central to the scientific study of skin aging and are a key component of the multibillion-dollar skincare industry.
"The joint study has the potential to significantly enhance our understanding of skin aging characteristics," said Fudi Wang, Principal Research Scientist at EveLab Insight and co-author of the study.
"EveLab Insight has played a crucial role in the experiment by providing precise and stable quantitative AI skin detection technology."
By enhancing the understanding of skin aging, this study paves the way for more effective and targeted skincare solutions in the future.

Abeona Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on:

Tuesday, August 8, 2023

CLEVELAND, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives.

Key Points:

CLEVELAND, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives.
Abeona anticipates submitting the BLA in the third quarter of 2023.
License and other revenues in the second quarter of 2023 were $3.5 million, compared to $1.0 million in the second quarter of 2022.
Abeona Therapeutics will host a conference call and webcast today, August 8, 2023, at 8:30 a.m.

Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models

Retrieved on:

Monday, May 29, 2023

Osaka University, Kyoto, Patient, Keio University, Kyoto University, ISID, Immunoglobulin G, Vaccine, Regulatory T cell, Pemphigus

OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.

Key Points:

OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.
Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and other autoimmune markers related to Pemphigus.
Collaborators also reported that S/F-iTregs generated from samples obtained from patients with Pemphigus also showed potent inhibition of autologous T cell proliferation in vitro.
Tregs play a central role in managing immune self-tolerance and depleted or dysfunctional Tregs are characteristic of many autoimmune disorders.

Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models

Retrieved on:

Monday, May 29, 2023

Osaka University, Kyoto, Patient, Keio University, Kyoto University, ISID, Immunoglobulin G, Vaccine, Regulatory T cell, Pemphigus

OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.

Key Points:

OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.
Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and other autoimmune markers related to Pemphigus.
Collaborators also reported that S/F-iTregs generated from samples obtained from patients with Pemphigus also showed potent inhibition of autologous T cell proliferation in vitro.
Tregs play a central role in managing immune self-tolerance and depleted or dysfunctional Tregs are characteristic of many autoimmune disorders.